Sunday, December 22

New Delhi: The Bureau of Indian Standards (BIS) Integrated Management System (IMS) has certified the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) under the aegis of Union Ministry of AYUSH. The AYUSH ministry said “PCIM&H has been awarded with IS/ISO 9001:2015 for Quality Management System (QMS), IS/ISO 14001:2015 for Environmental Management System (EMS) and IS/ISO 45001:2018 for Occupational Health and Safety Management System (OHSMS). This achievement marks a significant advancement for the Ayush sector, paving the way for enhanced global recognition and setting a new standard for excellence in Indian Medicine and Homeopathy.” These accolades affirm PCIM&H’s commitment to upholding global standards of quality, environmental stewardship, and workplace safety. The certifications not only enhance PCIM&H’s operational efficiency but also support the Ministry of Ayush’s mission to promote high standards in Ayurveda, Siddha, Unani, and Homoeopathy, it said.

Raman Mohan Singh, Director of PCIM&H said “This certification system will help PCIM&H to enhance the operational efficiency and also will help to meet global quality standards. PCIM&H is developing the quality standards for Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) drugs in the form of Pharmacopoeia.” The IMS certification system will help to assure the adherence to international acceptance of the pharmacopoeia standards developed by PCIM&H for ASU&H drugs, Singh said.

Share.
Leave A Reply

Doctor Post is a health news portal tailored to provide updates for medical and healthcare professionals, while remaining open to others interested in accessing general health information. The content on Doctor Post is carefully created and/or edited by a dedicated team of doctors, healthcare researchers, and scientific writers.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version